Visiongain has published a new report on Anti-snoring Treatment Market Report to 2031. The market is segmented by devices, by surgery, and by end- users. By devices, the market is categorized as (Mandibular Advancement devices, Nasal Devices, Continuous Positive Airway Devices, Others), By Surgery (Radiofrequency Palatoplasty, Uvulopalatopharyngoplasty (UPPP), Tonsillectomy, Laser-assisted Uvulopalatoplasty, Others) By End User (Hospitals, Retail Pharmacies, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Anti-Snoring Treatment Companies. PLUS COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/anti-snoring-market/#download_sampe_div
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The advancement of anti-snoring devices and increasing prevalence of sleeping disorder are some of the factors driving the growth of the global anti-snoring treatment market.
COVID-19 Impact on the Global Anti-Snoring Treatment Market
The COVID-19 pandemic has hugely affected the global anti-snoring market due to series of lockdown and social distancing rules. In response to the COVID-19, the lockdown was initiated as a safety measure, implemented with isolation, social distancing, and quarantine. This will likely reduce community transmission; however, it is huge challenge for the sleep apnea patients. The OSA patients have high risk of hospitalization due to the COVID-19 outcome.
Advancement of anti-snoring devices.
Snoring occurs when the tongue and tissues of the mouth and throat become too relaxed, the air passing through develops vibrations in the tissue, and creates high snoring sound, due to which most of the people lose sleep. Snoring can be highly disruptive and may indicate obstructive sleep apnea (OSA) or more serious medical condition. The advanced anti-snoring devices are designed such as Mandibular advancement devices, Tongue stabilizing devices, among others.
Increasing Smoking and Alcohol Consumption
Obstructive sleep apnea (OSA) is a disorder, which is characterized by partial or complete upper airway collapse results in apnea during sleep. According to the National Institute of Health the prevalence of OSA in the USA has been estimated at around 15% in men and 5% in women aged between 30–70 years. OSA is common among people who consume alcohol, and smokes, as consumption of alcohol possibly increases upper airway collapsibility and contribute to a higher body mass index. The alcohol consumption and smoking among people are at high risk associated with snoring and contribute towards anti-snoring treatment market.
Increasing awareness about sleep apnea and treatment
According to the American Sleep Apnea Association, nearly 22 million Americans suffers from Sleep apnea. The untreated apnea results in serious health consequences, however, in recent years the awareness among people is increasing for sleep apnea, and the availability of devices are one of the factors boosting the anti-snoring treatment market globally.
Get Detailed TOC @ https://www.visiongain.com/report/anti-snoring-market/#download_sampe_div
Apnea Sciences Corporation, Medtronic Plc, ASF Medical GmbH (Tomed GmbH), Fisher & Paykel Healthcare Limited, Koninklijke Philips NV, Meditas Ltd., Whole You Inc., ResMed Corp., SomnoMed Limited, The Pure Sleep Company are some of the key players contributing to the growth of the global anti-snoring treatment market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.
For instance, in March 2019, Apnea Sciences Corporation Launched SnoreRx at Walgreens Apnea Sciences. The US FDA cleared SnoreRx as an oral appliance for OTC treatment, which will be available at CVS pharmacies without a prescription.
In April 2019, ResMed launched AirFit P30i, its second top-of-head-connected CPAP mask for treating sleep apnea, a new nasal pillows option. The AirFit30i provides easy movement and enables home medical equipment (HME) providers to fit patients easier and faster.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email email@example.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Anti-snoring treatment market and leading companies. You will find data, trends and predictions.
Find more Visiongain research reports on Therapeutic Drugs Sector click on the following links:
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: firstname.lastname@example.org
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Follow Us: LinkedIn | Twitter
SOURCE Visiongain Limited.